製薬会社の意識調査で、肥満症患者の約9割が肥満は「自己責任」と捉えていることが、明らかになりました。
About 90% of patients with "obesity disease" in Japan perceive the medical condition as a personal responsibility, according to an awareness survey conducted by pharmaceutical firms.
※※obesity（病的な）肥満、太りすぎ≧overweight
※perceive 知覚する、認識する
日本肥満学会はBMI25以上を肥満としています。
The Japan Society for the Study of Obesity (JASSO) defines "obesity" as having a body mass index (BMI) of 25 or higher.
※define定義する
算出方法はBMI＝体重kg ÷ (身長m)2です。
BMI is calculated by dividing your weight in kilograms by your height in meters squared.
※square二乗する
BMIは筋肉や骨格の量、体脂肪率といった体の組成は考慮されておらず、健康と必ずしも一致していません。
The current one-size-fits-all BMI threshold doesn't take into account body composition, such as muscle mass, bone density, or body-fat percentage.
※one-size-fits-all フリーサイズの、汎用的な
※threshold 境界線、閾
※body composition 身体の組成
※muscle mass 筋肉量
※bone density 骨密度
※ body-fat percentage 体脂肪率
日本人女性の間で、低体重が増加しており、肥満への汚名、偏見が根深いと推定されます。
According to the health ministry’s National Health and Nutrition Survey, 21% of women in their 20s were classified as underweight, with a body mass index (BMI) of less than 18.5. The percentage has been on an upward trend since 1981, when 13% of women were classified as underweight. It has become clear that the stigma against obesity is more deeply rooted than expected.
※classify分類する
※stigma=〔社会的な〕烙印、汚名、不名誉のしるし［証拠］
☆（街角インタビューより）痩せていればいるほど綺麗だ。The thinner you are, the more beautiful you are.
しかし標準体型と比較すると、低体重は将来の妊娠で子供への影響リスクが上がります。
The issue is likely to have an impact on the next generation. It has been reported that the risk of giving birth to a low birth weight infant is 1.5 times greater for underweight women compared to women with a standard physique. The risk of premature birth is also increased.
※low birth weight infant ＝低出生体重児（2500キロ以下）
※premature birth早産、低体重児の出産 ➾preemie 〈米話〉未熟児、早産児
※体形 physique（特に男性）figure （特に女性）
低体重児の将来のリスクを示す研究もあります。
Studies in Japan and abroad have shown that low birth weight babies are more likely to have diabetes, heart disease, and high blood pressure in adulthood.
※diabetes 糖尿病
※heart disease 心臓疾患
※high blood pressure 高血圧 ➾hypertension
米国の製薬会社は、内臓脂肪の蓄積の悩みをターゲットにした脂肪代謝を促進し、食欲を抑制する薬を日本で発売しました。
U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat. The medicine works in the same way as hormones in the body that promote fat metabolism and suppress appetite.
※scourge苦悩のもと、悩み（の種）
※visceral 内臓の、内臓に関する、〔病気が〕内臓を冒す
※ fat metabolism 脂肪代謝
※ suppress appetite 食欲を抑える
糖尿病の薬を本来の用法でないダイエット目的で買う人もおり、必要な患者が買えない事態への対応も必要です。
Japan tackles surge in off-label diabetes drug use for weight loss（タイトル）
A diabetes medication has become so popular over the internet as a weight loss supplement that doctors are concerned it will be unavailable for patients who really need it. Its soaring popularity led to a rise in off-label prescriptions for weight loss.
※off-label use 承認済みの医薬品を、添付文書（製品情報）に記載されている効能・効果、用法・用量以外の目的で使用すること
